

RealRate

PHARMACEUTICAL 2023

Terns Pharmaceuticals Inc. Rank 18 of 446









RealRate

PHARMACEUTICAL 2023

Terns Pharmaceuticals Inc. Rank 18 of 446



The relative strengths and weaknesses of Terns Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Terns Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Terns Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 237% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	285,185
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,468
Liabilities, Non-Current	544
Other Assets	1,084
Other Compr. Net Income	-484
Other Expenses	358
Other Liabilities	1,071
Other Net Income	2,042
Other Revenues	0
Property and Equipment	757
Research and Development	39,617
Selling, General and Administrative Expense	22,412

Output Variable	Value in 1000 USD
Assets	287,026
Liabilities	10,083
Expenses	62,387
Revenues	0
Stockholders Equity	276,943
Net Income	-60,345
Comprehensive Net Income	-60,587
Economic Capital Ratio	280%

